Results 21 to 30 of about 17,461 (174)

Atypical Hemolytic Uremic Syndrome [PDF]

Seminars in Nephrology, 2013
Hemolytic uremic syndrome (HUS) is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. The atypical form of HUS is a disease characterized by complement overactivation. Inherited defects in complement genes and acquired autoantibodies against complement regulatory proteins have been described.
Kavanagh D, Goodship TH, Richards A
openaire   +3 more sources

RpoS impacts global gene expression and carbon source utilization in Escherichia coli O104:H4

Frontiers in Microbiology
BackgroundEscherichia coli (E. coli) O104:H4 caused the 2011 enterohemorrhagic E. coli (EHEC) outbreak in Germany, which remains the outbreak with the highest incidence of hemolytic uremic syndrome worldwide. We recently identified an E.
Petya Berger, Petya Berger, Karla Bosse-Plois, Wolfgang Pölking, David Loewe, Ian U. Kouzel, Michael Berger, Ulrich Dobrindt, Alexander Mellmann, Alexander Mellmann   +9 more
doaj   +1 more source

Hemolytic Uremic Syndrome Incidence in New York

Emerging Infectious Diseases, 2004
A comparison of New York’s traditional communicable disease surveillance system for diarrhea-associated hemolytic uremic syndrome with hospital discharge data showed a sensitivity of 65%. Escherichia coli O157:H7 was found in 63% of samples cultured from
Hwa-Gan H. Chang, Boldtsetseg Tserenpuntsag, Marilyn Kacica, Perry F. Smith, Dale L. Morse   +4 more
doaj   +1 more source

Hemolytic uremic syndrome [PDF]

Türk Pediatri Arşivi, 2015
Hemolytic uremic syndrome (HUS) is a clinical syndrome characterized by the triad of thrombotic microangiopathy, thrombocytopenia, and acute kidney injury. Hemolytic uremic syndrome represents a heterogeneous group of disorders with variable etiologies that result in differences in presentation, management and outcome.
openaire   +2 more sources

Adult hemolytic uremic syndrome

Revista del Hospital Italiano de Buenos Aires, 2023
Hemolytic uremic syndrome (HUS), described in 1955, is characterized by the triad of non-immune mediated hemolytic anemia, thrombocytopenia, and acute kidney injury. Shiga toxin, produced most frequently by E coli O157:H, is involved in its pathogenesis.
Micaela Viciconte, Lucas Fernández Otero   +1 more
doaj   +1 more source

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

Arthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya, Sandra G. Williams, Raphael A. Kirou, Marissa Lightbourne, Rebecca J. Brown   +4 more
wiley   +1 more source

Identification of Clinical Factors Associated With the Immunogenicity of Homologous ChAdOx1‐nCoV‐19 Vaccine in Hemodialysis Patients

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hemodialysis (HD) patients are at higher risk of severe COVID‐19 and may exhibit suboptimal vaccine responses. This study evaluates the factors influencing vaccine‐induced immunity in HD patients following the second dose of the Vaxzevria. A total of 276 HD patients and 126 controls were included. Antibody responses were assessed using binding
Chia‐Wei Chang, Ping‐Hsun Wu, Li‐Yun Chang, Yu‐Ying Huang, Teng‐Hui Huang, Su‐Chu Lee, Yi‐wen Chiu, Shang‐Jyh Hwang, Tsun‐Yung Kuo, Mei‐Chuan Kuo   +9 more
wiley   +1 more source

Hemolytic uremic syndrome with multiple organ involvement secondary to complement factor H p.Arg1215X mutation

The Turkish Journal of Pediatrics, 2017
Complement mediated hemolytic uremic syndrome which is caused by excessive activation of the alternative complement system is a thrombotic microangiopathy.
Osman Yeşilbaş, Esra Şevketoğlu, Mey Talip Petmezci, Hasan Serdar Kıhtır, Meryem Benzer, Afig Berdeli   +5 more
doaj   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

The FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin, Sumit Bhutada, Suneel S. Apte   +2 more
wiley   +1 more source